In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report), with a price target of $21.00. The company’s shares closed last Friday at $8.68.
According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -23.4% and a 27.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Applied Genetic Technologies, and Lineage Cell Therapeutics.
Nuvectis Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $21.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $20.92 and a one-year low of $3.08. Currently, Nuvectis Pharma has an average volume of 32.7K.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVCT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its pipeline products include NXP800, NXP900.
Read More on NVCT:
